Article Text

Download PDFPDF
Association of Metformin Use and Survival Outcome in Women With Cervical Cancer
  1. Tsuyoshi Takiuchi, MD, PhD*,
  2. Hiroko Machida, MD*,
  3. Marianne S. Hom, MD*,
  4. Sayedamin Mostofizadeh, MD*,
  5. Marina Frimer, MD,
  6. Laurie L. Brunette, MD* and
  7. Koji Matsuo, MD, PhD*,
  1. * Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California;
  2. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; and
  3. Hofstra Northwell School of Medicine, Long Island, NY.
  1. Address correspondence and reprint requests to Koji Matsuo, MD, PhD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California 2020 Zonal Ave, IRD 520 Los Angeles, CA 90033. E-mail: koji.matsuo{at}med.usc.edu.

Abstract

Objective Although preclinical studies suggest possible antitumor effects of metformin against cervical cancer, there is currently a lack of clinical data examining the association of metformin use and survival in women with cervical cancer. The aim of this study was to examine survival of women with cervical cancer who were receiving metformin.

Methods This is a retrospective study examining consecutive cases of stages I to IV cervical cancer between 2000 and 2014. Patient demographics, medication use, tumor characteristics, treatment patterns, and survival outcomes were correlated to metformin use.

Results There were 70 (8.9%; 95% confidence interval [CI], 6.9–10.9) metformin users and 715 nonusers identified for the analysis. Median follow-up time was 22.6 months. Recurrence/progression of disease and death due to cervical cancer were observed in 236 and 163 cases, respectively. Metformin users were more likely to be older, hypertensive, diabetic, and dyslipidemic compared with nonusers (all, P < 0.05). On univariate analysis, metformin users and nonusers had similar progression-free survival (PFS) (5-year rates; 57.3% vs 61.8%; P = 0.82) and cervical cancer–specific overall survival (71.7% vs 70.7%; P = 0.86). After adjusting for patient demographics and tumor characteristics, metformin use was not associated with PFS (adjusted hazards ratio, 1.11; 95% CI, 0.70–1.74; P = 0.67) or cervical cancer–specific overall survival (adjusted hazards ratio, 0.91; 95% CI, 0.52–1.60; P = 0.75). Among 478 women who received whole pelvic radiotherapy, metformin use was not associated with PFS (P = 0.93) or cervical cancer–specific overall survival (P = 0.32).

Conclusions In this study population, metformin use was not associated with survival of women with cervical cancer.

  • Cervical cancer
  • Metformin
  • Radiotherapy
  • Survival

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.